Mutations on non-structural proteins of SARS-CoV-2 are possibly responsible for

adverse clinical outcomes

Takaya Ichikawa[1], Shiho Torii[2], Hikoyu Suzuki[3], Akio Takada[4], Satoshi Suzuki[1], Masahide

Nakajima[5], Akihito Tampo[6], Yasutaka Kakinoki[1]

1. Division of Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan

2. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University,

Suita, Japan

3. digzyme Inc., Tokyo, Japan

4. Department of Pathology, Asahikawa City Hospital, Asahikawa, Japan

5. Department of Pediatrics, Asahikawa City Hospital, Asahikawa, Japan

6. Department of Emergency Medicine, Asahikawa City Hospital, Asahikawa, Japan

Corresponding author

Takaya Ichikawa, D.V.M., M.D.

Asahikawa City Hospital, 1-1-65, Kinsei-cho, Asahikawa, Hokkaido, Japan

e-mail: ichikawa.honest2.go@gmail.com

Keywords: COVID-19, SARS-CoV-2, non-structural protein, mutation, clinical outcome

Abstract

Among a cluster of COVID-19 cases from the end of March through April 2021 in Asahikawa, we

experienced the cases in which patients manifested severe clinical symptoms compared to patients

who were infected before that. A hundred three patients (age range: 65 to 89 years old) enrolled in this

study were divided into two groups, group A: the patients infected from November 2020 to March

2021, and group B: the patients in this cluster population. The mortality rates were 6.1% in group A

and 16.2% in group B (OR: 2.97, 95%CI: 0.65-15.38). For the severity of disease, the patients in group

B required higher oxygen flow rate in early course of admission (mild; p=0.892, moderate; p=0.117,

severe; p=0.029). Whole viral genome sequences revealed five non-synonymous mutations by

comparison of the isolates with each group. Of these, four were on non-structural proteins (NSPs)

including nsp3, 6 and 15, and one was on S protein located near the C-terminus, suggesting that the

mutations on NSPs could be responsible for adverse clinical outcomes in COVID-19 patients.

Introduction

The Coronavirus disease 2019 (COVID-19), which is caused by Severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2), initially broke out in Wuhan, China, on December 2019 and has

subsequently spread around the world [1]. SARS-CoV-2 is an enveloped virus with a positive-sense

single-stranded RNA genome of approximately 30 kb. Two-thirds of the viral genome at the 5'

terminus contains ORF1a and ORF1b, which encodes 16 non-structural proteins (NSPs). These NSPs

play crucial roles in viral replication and evasion of host immune systems [2]. The other one-third of

the 3' end contains structural genes such as spike glycoprotein (S protein), envelope protein, membrane

protein, nucleocapsid protein, and several accessory proteins [3]. Because replication of RNA viruses

typically has a low fidelity, the viral genome of SARS-CoV-2 has accumulated mutations at an average

of two nucleotides per month [4]. On 25th February 2021, World Health Organization (WHO) defined

a variant of interest (VOI) as an isolate detected in several countries that changes phenotype under

certain conditions, and a variant of concern (VOC) as an isolate in VOIs if it has been demonstrated

to be associated with increase in transmissibility or virulence

(https://www.who.int/emergencies/diseases/novel-coronavirus-2019). For example, VOC-202012/01

(Pango lineage B.1.1.7), as it is called "alpha variant", has higher transmissibility and mortality

compared to a reference isolate [5,6]. These variants, however, were not focused on mutations in NSPs,

but in structural proteins, especially S protein. It remains unclear whether mutations in NSPs are

responsible for the virulence of COVID-19.

As of October 2021, COVID-19 is responsible for 1.7 million cases and 18 thousand deaths

in Japan (https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html). The most remarkable

clinical feature of this disease is its heterogeneity in clinical manifestations, ranging from no symptoms

to critical illness [7]. Several risk factors for symptom severity have been known, such as age (over

65 years old), male sex, obesity, history of smoking, and comorbidities (including hypertension,

diabetes mellitus, respiratory disease, cardiovascular disease, chronic kidney disease and cancer)

[8,9,10,11]. In Japan, the several treatment options are currently recommended based on the symptom

severity: Casirivimab and Imdevimab, remdesivir, dexamethasone and baricitinib

(https://www.mhlw.go.jp/content/000815065.pdf). In clinical practice, methylprednisolone is also

used for critically ill patients when they have a poor response for the dexamethasone therapy or when

baricitinib is not available [12].

In Asahikawa city, Hokkaido prefecture located in northern part of Japan, A cluster of

COVID-19 cases occurred in several bars where a group of customers enjoyed "karaoke" during

daytime from the end of March through April 2021 (referred to bellow as cluster K), and 66 cases were

involved into the infection according to the city's survey

(https://www.city.asahikawa.hokkaido.jp/kurashi/135/136/150/index.html). We found that the

progression of disease among the patients in this cluster were faster compared to patients who were

infected before that. Therefore, in order to identify factors associated with the progression of disease,

we examined the viral genome sequences along with the clinical characteristics and treatment

strategies, and then compared those with other cases.

Material and Method

Participants

All adult patients with COVID-19 who were admitted to Asahikawa City Hospital from November

2020 to April 2021 were enrolled in this retrospective study. All positive results were confirmed by

real-time RT-PCR for the presence of SARS-CoV-2 in saliva or nasopharyngeal swab samples. The

recovered patients were discharged from the hospital following the discharge criteria provided by

Japanese Ministry of Health, Labour and Welfare when two criteria have met:10 days passed from the

symptom onset and 72 hours passed from the symptom resolution, or when two consecutive negative

PCR results are confirmed. Opt-out consent was obtained instead of written informed consent. We

provided the patients with information explaining the proposed research plan via the website of

Asahikawa City Hospital, and with the opportunity to opt out.

Clinical data collection and definitions

The epidemiological data, medical history, underlying comorbidities, symptoms and signs at

admission, oxygen flow rate, treatment and clinical outcomes were obtained from electronic medical

records. Because the date of onset was unclear for some patients who were asymptomatic, we

considered the date on which positive PCR result was obtained as day 0. Clinical outcomes were

followed up until discharge or death. The primary outcome was mortality rate, and the secondary

outcome was oxygen flow rate as a severity of the disease; mild: ≥ 1 L/min, moderate: ≥ 5 L/min and

severe: ≥ 10 L/min.

Viral genome sequence

The stored RNA extracts were used as clinical samples. Fist-strand cDNA was synthesized by using a

PrimeScript IV 1st strand cDNA Synthesis Mix (TaKaRa Bio) with random hexamer primers and

extracted RNA, according to the manufacture's protocols. The whole-genome sequencing of SARS-

CoV-2 was carried out as reported previously [13]. Briefly, a total of 10 gene fragments were amplified

with synthesized cDNA, specific primer sets for SARS-CoV-2 and PrimeSTAR GXL DNA

polymerase (TaKaRa Bio). Then, the amplified products were directly sequenced in both directions by

using the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems) with specific primers. Our raw

sequence data were converted to FASTQ format by in-house Python script with BioPython module

[14], followed by trimming first 50 bps and the region after 900 bps by FASTX-Toolkit

(http://hannonlab.cshl.edu/fastx_toolkit/). Trimmed sequence reads were mapped to the SARS-CoV-2

reference genome (accession number MN908947.3).

Phylogenetic analysis

More than one million SARS-CoV-2 published genome sequences whose length were between 29,000

- 30,000 bps were downloaded from National Center for Biotechnology Information (NCBI) via

Application Programming Interface (API) for the Entrez Programming Utilities (E-utilities)

(https://www.ncbi.nlm.nih.gov/books/NBK25497/). Sequences including less than 29,000 definite

bases, neither 'N' nor other mixed bases, were discarded.

All SARS-CoV-2 genome sequence data, including our assemblies, were mapped to the

reference genome (accession number MN908947.3). Based on the SAM format mapping output, SNPs

and short INDELs were detected and categorized to synonymous, non-synonymous or intergenic

mutations by in-house Perl scripts, which simply picked up the differences from the reference

sequence for each genome. For the phylogenetic analysis, a typical genome sequence of each variant,

named alpha, beta, gamma, delta, epsilon, zeta, eta, theta, iota, kappa, and lambda by WHO, were

chosen from the published data based on the following criteria; neither 'N 'nor other mixed bases

were included in open reading frames (ORFs), number of substitution sites in ORFs were less than

100, all non-synonymous mutations which characterize each variant were included, and all other

substitutes observed in more than 95% of the samples that satisfy the above conditions were also

included. The non-synonymous mutations which characterize each variant are shown in Table S1,

created based on the mutation prevalence information from outbreak.info (https://outbreak.info/).

ORF10 was excluded from the analyses because one of our assemblies did not completely cover that

region. Based on the alignment, suitable nucleotide substitution models for each partition were

selected by ModelTest-NG [15], followed by maximum likelihood phylogenetic analyses using the

selected substitution models by RAxML-NG [16]. The constructed phylogenetic tree was drawn and

edited by MEGA X [17].

Statistical analysis

We performed group comparisons using Fisher's exact test for categorical variables, and independent

group t-test for continuous variables. The categorical variables were expressed as frequencies

(percentage), and the continuous variables as the median with interquartile range. Odds ratios (OR)

with 95% confidence interval were calculated for the rates of mortality and the required oxygen flow

rate. Cumulative probabilities of oxygen therapy were described with using the Kaplan-Meier analysis

and compared using log-rank test. P-values of 0.05 or less were considered statistically significant. All

statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University,

Saitama, Japan, version 1.54) [18], which is a graphical user interface for R software (The R

Foundation for Statistical Computing, Vienna, Austria).

Result

A total of 191 patients diagnosed with COVID-19 were admitted to our hospital from November 2020

to April 2021. The patients were divided into two groups, group A: the patients infected from

November 2020 to March 2021, and group B: the patients whose infection was traced from the cluster

K. We included the patients whose ages range between 65 and 89 years old for the following reasons;

1) patients who are younger than 65 years old are not necessarily requested for hospitalization in our

city's health care system, 2) in group A, many patients over 90 years old were transferred from a

convalescent hospital where COVID-19 outbreak had occurred, thus the age profiles would be much

different from group B if the patients aged over 90 years old were included in this group. Finally, 66

patients were assigned to group A and 37 patients to group B (Figure 1).

The clinical characteristics and treatment strategies used during hospitalization are shown

in Table 1. Although there were no significant differences in clinical characteristics between the two

groups, obesity and lifestyle-related diseases such as hypertension, dyslipidemia and diabetes tended

to be more prevalent in group B. In treatment strategies, remdesivir tended to be used more frequently

in group A and methylprednisolone in group B.

Four patients of 66 patients (6.1%) in group A and six of 37 patients (16.2%) in group B

died from COVID-19 (OR: 2.97, 95%CI: 0.65-15.38) (Table 2). When limited to males, the differences

in number of deaths became larger (6.3% vs 29.4%, OR: 5.99, 95%CI: 0.84-71.2). The clinical

characteristics and the treatment of 10 deceased patients are shown in Table S2. Cumulative

probability of the patients who required minimal oxygen therapy (mild) were similar in both groups

(Table 2, Figure 2A). However, the patients in group B were likely to require more oxygen therapy in

earlier course of hospitalization (Figure 2B, 2C). There was no significant difference in the cumulative

probability between two groups for moderate oxygen therapy (p=0.117), but for severe oxygen therapy,

the significant difference was observed (p=0.029). As with mortality, males in group B showed worse

outcomes in the severity of disease (Table 2).

Assuming that these differences in clinical outcomes would be due to viral factors, we

examined the whole viral genome sequences representing two samples in each group, named

Asahikawa_0108 and Asahikawa_0122 isolated in January 2021, Asahikawa_0404 and

Asahikawa_0417 isolated in April 2021. The mutation sites which differed in these four samples are

summarized in Table 3. Focusing on the non-synonymous mutations, five amino acid changes were

identified (represented in bold). Of these, four amino acid changes were located on NSPs and one was

on S protein, as illustrated in the viral genome scheme of SARS-CoV-2 (Figure 3). In order to assess

strain relatedness, the phylogenetic analysis was carried out. The isolates in this study were closely

related to the strain previously isolated in Japan (accession number BS000756.1; Pango lineage

B.1.1.214), but not to any of the variants labeled by WHO (Figure 4).

Discussion

We here experienced the cases of a single COVID-19 cluster in which the conventional treatment was

unsuccessful and the hospitalized patients became more severely ill, thus performed the retrospective

analysis to find out the causative factors. The patients in group B had a higher mortality rate compared

to group A, but no significant difference was indicated. For the severity of disease, the patients in

group B required higher oxygen flow rate in early course of admission. Furthermore, the differences

became larger when limited to males, with 41.2% of male severe patients in group B against 6.3% in

group A.

In terms of treatment strategies, we were likely to use methylprednisolone monotherapy for

severe cases in group B. This was because we had experienced that, in the winter of 2020, patients

who received methylprednisolone therapy appeared to have a better response than those who were

treated with remdesivir after poor response for dexamethasone, although the treatment guideline for

COVID-19 in Japan recommends the use of remdesivir for patients with pneumonia whose oxygen

saturation falls below 96% (https://www.mhlw.go.jp/content/000815065.pdf). In our study, there was

no significant difference of remdesivir usage between two groups, thus the viral factors could have an

impact on the clinical outcomes.

Whole viral genome sequences revealed five non-synonymous mutations by comparison of

the isolates with each group. Interestingly, four of them were on NSPs. The sole structural mutation,

D1153G on S protein, was located near the C-terminus and outside the range of three-dimensional

structures obtained by crystallography, suggesting neither the head nor stalk of S protein. Therefore,

D1153G is not expected to involve in the virulence of the disease. Of the four mutation sites on NSPs,

two were found on nsp6 (T3598I and Y3722C), and the rest of them were on nsp3 (E2089D) and

nsp15 (A2143S). To our knowledge, none of these mutations are known to be the factors that determine

the severity of disease in clinical practice, and it is unclear whether the mutations affect the functions

of these NSPs. However, all of them have been reported to play roles in suppression of type 1 interferon

in host cells [19,20,21], and also nps6 involves in the formation of autophagosome in host cells [22].

The potential sites under positive selective pressure have been found on nsp6 near T3598I according

to an evolutionary analysis on SARS-CoV-2 genome sequences of 351 clinical samples [23]. Therefore,

the mutations on nsp3, 6 and 15 could be responsible for its function to interact with host immunity

and autophagy. Further investigations are required to reveal their functions and involvement in the

virulence.

The phylogenetic analysis revealed that the isolates in this study are derived from Pango

lineage B.1.1.214 which was the dominant strain in so-called "the third wave", the epidemic period

from October to December 2020 in Japan [24]. Considering the fact that any strains identical to the

viral sequence of group B cannot be found in more than 1,000,000 registered sequences in NCBI, it is

likely that the virus evolved locally from January to April 2021 in Hokkaido. Since May 2021, alpha

variant has been dominant throughout Japan including Hokkaido; 78% of the samples isolated from

April   26   to   May   2   2021   in   Hokkaido   were   already   alpha   variant

(https://www.mhlw.go.jp/content/10900000/000779013.pdf). As a consequence, B.1.1.214 strains in

Asahikawa seems to be eliminated. This is similar to the situation in influenza A virus, for example,

where pandemic influenza A (H1N1) pdm09 replaced Russian flu (H1N1) since 2009 [25,26].

There are some limitations to this retrospective study. First, the recommended therapy for

COVID-19 have been changing dynamically. Because the best treatment strategies are selected based

on the evidence at that time, it is difficult to compare clinical outcomes between different periods of

time in real-life practice. Second, this is a single institution study; not all cases in cluster K have been

assessed. The mortality and severity rate would be different when including the cases admitted to other

hospitals. Third, we examined only two samples from each group in this study. Due to the limited

human and financial resources, we were unbale to perform the viral genome analysis of much more

samples.

In conclusion, the present study demonstrated that some viral factors, four non-synonymous

mutations on nsp3, 6 and 15 but not on S protein, could be responsible for adverse clinical outcomes

in COVID-19 patients. Though scientists and physicians all over the world have focused on the S

protein mutations, in order to comprehensively understand the epidemiology of COVID-19, we should

have an insight into other type of mutations such as those on NSPs.

Acknowledgment

We thank Prof. Yoshiharu Matsuura, Osaka University, for funding the viral sequence analysis. We

also thank our medical team worked on COVID-19 and all of the staff at Asahikawa Health Center for

their support.

Declaration of interests

Authors have no conflicts of interests.

Reference

1.   Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species

Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it

SARS-CoV-2. Nat Microbiol. 2020;5: 536–544. doi:10.1038/s41564-020-0695-z

2.   Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. Coronaviruses Methods

Protoc. 2015;1282: 1–282. doi:10.1007/978-1-4939-2438-7

3.   Hagemeijer MC, Verheije MH, Ulasli M, Shaltiël IA, de Vries LA, Reggiori F, et al. Dynamics of

Coronavirus Replication-Transcription Complexes. J Virol. 2010;84: 2134–2149.

doi:10.1128/jvi.01716-09

4.   Duchene S, Featherstone L, Haritopoulou-Sinanidou M, Rambaut A, Lemey P, Baele G. Temporal

signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 2020;6: 1–8.

doi:10.1093/ve/veaa061

5.   Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated

transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-). 2021;372.

doi:10.1126/science.abg3055

6.   Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of

mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort

study. BMJ. 2021;372: 1–10. doi:10.1136/bmj.n579

7.   Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline

Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of

the Lombardy Region, Italy. JAMA - J Am Med Assoc. 2020;323: 1574–1581.

doi:10.1001/jama.2020.5394

8.   Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Since January 2020 Elsevier has created a COVID-

19 resource centre with free information in English and Mandarin on the novel coronavirus

COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s

public news and information . 2020.

9.   Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity

and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev.

2020;21: 1–17. doi:10.1111/obr.13128

10.   Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol.

2020;16: 705–706. doi:10.1038/s41581-020-00349-4

11.   Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection:

a nationwide analysis in China. Lancet Oncol. 2020;21: 335–337. doi:10.1016/S1470-

2045(20)30096-6

12.   Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs

methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16: 1–13.

doi:10.1371/journal.pone.0252057

13.   Torii S, Ono C, Suzuki R, Morioka Y, Anzai I, Fauzyah Y, et al. Establishment of a reverse genetics

system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 2021;35: 109014.

doi:10.1016/j.celrep.2021.109014

14.   Cock PJA, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: Freely available

Python tools for computational molecular biology and bioinformatics. Bioinformatics. 2009;25:

1422–1423. doi:10.1093/bioinformatics/btp163

15.   Darriba Di, Posada D, Kozlov AM, Stamatakis A, Morel B, Flouri T. ModelTest-NG: A New and

Scalable Tool for the Selection of DNA and Protein Evolutionary Models. Mol Biol Evol. 2020;37:

291–294. doi:10.1093/molbev/msz189

16.   Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: A fast, scalable and user-

friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35: 4453–

4455. doi:10.1093/bioinformatics/btz305

17.   Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary genetics

analysis across computing platforms. Mol Biol Evol. 2018;35: 1547–1549.

doi:10.1093/molbev/msy096

18.   Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics.

Bone Marrow Transplant. 2013;48: 452–458. doi:10.1038/bmt.2012.244

19. Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease

regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587: 657–662.

doi:10.1038/s41586-020-2601-5

20. Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al. Evasion of Type I Interferon

by SARS-CoV-2. Cell Rep. 2020;33: 108234. doi:10.1016/j.celrep.2020.108234

21. Yuen C-K, Lam J-Y, Wong W-M, Mak L-F, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14,

nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9: 1418–

1428. doi:10.1080/22221751.2020.1780953

22. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome

expansion. Autophagy. 2014;10: 1426–1441. doi:10.4161/auto.29309

23. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et al.

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6

(NSP6) could affect viral autophagy. J Infect. 2020;81: e24–e27.

doi:10.1016/j.jinf.2020.03.058

24. National Institute of Infectious Diseases, Infectious Agents Surveillance Report. 2021;42: 61-64.

25. Blyth CC, Kelso A, McPhie KA, Ratnamohan VM, Catton M, Druce JD, et al. The impact of the

pandemic influenza a(H1N1) 2009 virus on seasonal influenza a viruses in the southern

hemisphere, 2009. Eurosurveillance. 2010;15: 1–5. doi:10.2807/ese.15.31.19631-en

26. Broor S, Krishnan A, Roy DS, Dhakad S, Kaushik S, Mir MA, et al. Dynamic patterns of

circulating seasonal and pandemic A(H1N1)pdm09 influenza viruses from 2007-2010 in and

around Delhi, India. PLoS One. 2012;7: 1–9. doi:10.1371/journal.pone.0029129

Table 1. Characteristics and treatment options of COVID-19 patients

Characteristic	Group A (N=66)	Group B (N=37)	P value
Age, median (IQR)	76 (71-85)	78 (74-82)	0.75
Male sex (%)	32 (48.5)	17 (45.9)	0.84
Duration of hospitalization, median (IQR)	12.5 (9-16)	11 (59-16)	0.85
Obesity, BMI ≥30 (%)	4 (6.1)	6 (16.2)	0.16
Current or ex-smoker (%)	21 (31.8)	13 (35.1)	0.83
Comorbidities (%)			
Hypertention	38 (57.6)	28 (75.7)	0.09
Dyslipidemia	21 (31.8)	16 (43.2)	0.29
Diabetes mellitus	12 (18.2)	10 (27.0)	0.32
Chronic pulmonary disease	12 (18.2)	11 (29.7)	0.22
Cardiovascular disease	10 (15.2)	7 (18.9)	0.78
Chronic kidney disease	10 (15.2)	6 (16.2)	1.00
Cancer	9 (13.6)	2 (5.4)	0.32
Treatment options (%)			
Dexamethasone	39 (59.1)	19 (51.4)	0.54
Methylprednisolone	10 (15.2)	11 (29.7)	0.12
Remdesivir	8 (12.1)	2 (5.4)	0.32

IQR: interquartile range, BMI: body mass index

319 **Table 2. Primary and secondary outcomes of COVID-19 patients**

Outcome	Over all			Male		
	Group A (N=66)	Group B (N=37)	OR (95%CI)	Group A (N=32)	Group B (N=17)	OR (95%CI)
Death (%)	4 (6.1)	6 (16.2)	2.97 (0.65-15.38)	2 (6.3)	5 (29.4)	5.99 (0.84-71.2)
Severity* (%)						
Mild	27 (40.9)	15 (40.5)	0.98 (0.40-2.41)	15 (46.9)	9 (52.9)	1.27 (0.34-4.89)
Moderate	9 (13.6)	9 (24.3)	2.02 (0.63-6.47)	4 (12.5)	8 (47.1)	5.95 (1.25-33.9)
Severe	5 (7.6)	8 (21.6)	3.32 (0.87-14.11)	2 (6.3)	7 (41.2)	6.68 (1.24-47.8)

* Oxygen flow rate: Mild ≥1 L/min, Moderate ≥5 L/min, Severe ≥10 L/min

Table 3. Mutation sites that differed in the four samples

Nucleotide position	Gene	Group A		Group B		Amino acid change
		Asahikawa_0108	Asahikawa_0122	Asahikawa_0404	Asahikawa_0417	
4233		G	A	A	A	D1323G
6380		C	T	C	C	L2039F
6433		T	C	C	C	Syn
6532		G	G	T	T	**E2089D**
6997		T	C	C	C	Syn
8371		T	G	G	G	Q2702H
8917	Orf1a	C	T	T	T	Syn
9207		T	C	C	C	S2981F
10042		A	A	G	G	Syn
11058		C	C	T	T	**T3598I**
11430		A	A	G	G	**T3722C**
12049		C	T	T	T	Syn
13366		C	C	T	T	Syn
15240		T	C	C	C	Syn
15957		G	A	G	G	Syn
17502	Orf1b	C	T	C	C	Syn
19894		G	G	T	T	**A2143S**
20658		A	G	A	A	Syn
22502		C	A	C	C	Q314K
23191		C	C	T	T	Syn
23587	S	G	T	T	T	Q675H
23720		G	A	A	A	I720V
24748		C	C	T	T	Syn
25020		A	A	G	G	**D1153G**
29353	N	C	T	T	T	Syn

Position number based on alignment to NCBI reference sequence: NC_045512 (Wuhan-Hu-1).
The different parts between the two samples in group A are shown in a gray area. Amino acid changes identified between two groups were represented in bold.

Figure Legends

Figure 1. Flow diagram indicating the recruitment process in this study.

Figure 2. Cumulative probability of the patients who required oxygen therapy with mild: ≥1 L/min,

moderate: ≥5 L/min and severe: ≥10 L/min. The log-rank test was used for statistical analysis.

Figure 3. Scheme of SARS-CoV-2 genome. The non-synonymous mutation sites are indicated by

arrows.

Figure 4. Maximum likelihood phylogenetic tree of SARS-CoV-2 variants. Black and rend characters

indicate synonymous and non-synonymous mutations respectively. Red bold characters indicate

mutations of interest. Numbers on internal nodes are bootstrap values for each divergence.

Figure 1

Figure 2

Figure 3

Figure 4